{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T08:57:00Z","timestamp":1771577820875,"version":"3.50.1"},"reference-count":50,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"vor","delay-in-days":365,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1016\/j.jval.2013.03.1625","type":"journal-article","created":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T19:31:17Z","timestamp":1372707077000},"page":"729-739","source":"Crossref","is-referenced-by-count":33,"title":["Cost-Effectiveness of the 21-Gene Assay for Guiding Adjuvant Chemotherapy Decisions in Early Breast Cancer"],"prefix":"10.1016","volume":"16","author":[{"given":"Mike","family":"Paulden","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob","family":"Franek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ba\u2019","family":"Pham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe L.","family":"Bedard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maureen","family":"Trudeau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murray","family":"Krahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jval.2013.03.1625_bib1","unstructured":"Adjuvant! Inc. Adjuvant! Online. 2011. Available from: http:\/\/www.adjuvantonline.com\/index.jsp. [Accessed December 2, 2011]."},{"key":"10.1016\/j.jval.2013.03.1625_bib2","unstructured":"Adjuvant! Inc. Comments on definition of relapse. 2011. Available from: http:\/\/www.adjuvantonline.com\/breasthelp0306\/CommentsOfDefinitionOfRelapse.html. [Accessed December 2, 2011]."},{"key":"10.1016\/j.jval.2013.03.1625_bib3","unstructured":"Bryant J. Toward a more rational selection of tailored adjuvant therapy: data from the National Surgical Adjuvant Breast and Bowel Project. Presented at: 9th International Conference on Primary Therapy of Breast Cancer; January 26-29, 2005; St. Gallen, Switzerland."},{"key":"10.1016\/j.jval.2013.03.1625_bib4","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1200\/JCO.2005.06.178","article-title":"Population-based validation of the prognostic model ADJUVANT! for early breast cancer","volume":"23","author":"Olivotto","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jval.2013.03.1625_bib5","unstructured":"I. Genomic Health. Oncotype DX: clinical summary. 2011. Available from: http:\/\/www.oncotypedx.com\/en-US\/Breast\/HealthcareProfessional\/ClinicalSummary.aspx. [Accessed December 2, 2011]."},{"key":"10.1016\/j.jval.2013.03.1625_bib6","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1056\/NEJMoa041588","article-title":"A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer","volume":"351","author":"Paik","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jval.2013.03.1625_bib7","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1200\/JCO.2005.04.7985","article-title":"Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer","volume":"24","author":"Paik","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jval.2013.03.1625_bib8","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1470-2045(09)70314-6","article-title":"Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial","volume":"11","author":"Albain","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jval.2013.03.1625_bib9","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1200\/JCO.2009.24.4798","article-title":"Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study","volume":"28","author":"Dowsett","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jval.2013.03.1625_bib10","unstructured":"I. Genomic Health. Quarterly report, 8 November 2011. 2011. Available from: http:\/\/biz.yahoo.com\/e\/111108\/ghdx10-q.html. [Accessed December 2, 2011]."},{"key":"10.1016\/j.jval.2013.03.1625_bib11","doi-asserted-by":"crossref","first-page":"347","DOI":"10.3816\/CBC.2006.n.051","article-title":"TAILORx: trial assigning individualized options for treatment (Rx)","volume":"7","author":"Sparano","year":"2006","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.jval.2013.03.1625_bib12","doi-asserted-by":"crossref","first-page":"603","DOI":"10.2217\/14796694.4.5.603","article-title":"Trial assessing individualized options for treatment for breast cancer: the TAILORx trial","volume":"4","author":"Zujewski","year":"2008","journal-title":"Future Oncol"},{"key":"10.1016\/j.jval.2013.03.1625_bib13","unstructured":"Medical Advisory Secretariat of the Ontario Ministry of Health and Long-Term Care. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer. 2010. Available from: http:\/\/www.health.gov.on.ca\/english\/providers\/program\/mas\/tech\/ohtas\/tech_gep_20101213.html. [Accessed December 2, 2011]."},{"key":"10.1016\/j.jval.2013.03.1625_bib14","unstructured":"Canadian Agency for Drugs and Technologies in Health. Guidelines for the Economic Evaluation of Health Technologies: Canada. Ottawa, Canada: the Canadian Agency for Drugs and Technologies in Health (CADTH), 2006."},{"key":"10.1016\/j.jval.2013.03.1625_bib15","unstructured":"O. I. for C. Research. Evaluating pharmacogenetic tests. 2010. Available from: http:\/\/oicr.on.ca\/report\/evaluating-pharmacogenetic-tests. [Accessed December 2, 2011]."},{"key":"10.1016\/j.jval.2013.03.1625_bib16","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1634\/theoncologist.2009-0275","article-title":"Cost-effectiveness analysis of recurrence score-guided treatment using a 21-gene assay in early breast cancer","volume":"15","author":"Tsoi","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.jval.2013.03.1625_bib17","doi-asserted-by":"crossref","unstructured":"Lo SS, Mumby PB, Norton J, et al. Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. J Clin Oncol 2010;28:1671\u201376.","DOI":"10.1200\/JCO.2008.20.2119"},{"key":"10.1016\/j.jval.2013.03.1625_bib18","unstructured":"Canadian Institute for Health Information. Available from: http:\/\/www.cihi.ca. [Accessed February 27, 2013]."},{"key":"10.1016\/j.jval.2013.03.1625_bib19","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1200\/JCO.2008.18.4028","article-title":"Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US oncology research trial 9735","volume":"27","author":"Jones","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jval.2013.03.1625_bib20","doi-asserted-by":"crossref","unstructured":"Roch\u00e9 H, Fumoleau P, Spielmann M, et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol;24:5664\u201371.","DOI":"10.1200\/JCO.2006.07.3916"},{"key":"10.1016\/j.jval.2013.03.1625_bib21","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1200\/JCO.2001.19.3.602","article-title":"Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial","volume":"19","author":"French Adjuvant Study Group","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jval.2013.03.1625_bib22","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1200\/JCO.1990.8.9.1483","volume":"8","author":"Fisher","year":"1990","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jval.2013.03.1625_bib23","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1200\/JCO.1996.14.1.35","article-title":"Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial","volume":"14","author":"Coombes","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jval.2013.03.1625_bib24","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJM198902233200804","article-title":"Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer","volume":"320","author":"Ludwig Breast Cancer Study Group","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jval.2013.03.1625_bib25","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/cncr.11083","article-title":"Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor","volume":"97","author":"Chang","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.jval.2013.03.1625_bib26","unstructured":"Statistics Canada. Complete life table, Ontario, 2000 to 2002: females. 2002. Available from: http:\/\/www.statcan.gc.ca\/pub\/84-537-x\/4064441-eng.htm. [Accessed December 2, 2011]."},{"key":"10.1016\/j.jval.2013.03.1625_bib27","unstructured":"Bank of Canada. USD\/CAD closing rate summary. 2011. Available from: http:\/\/www.bankofcanada.ca\/rates\/exchange\/us-can-summary\/. [Accessed November 21, 2011]."},{"key":"10.1016\/j.jval.2013.03.1625_bib28","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/S0959-8049(99)00340-8","article-title":"Estimates of the lifetime costs of breast cancer treatment in Canada","volume":"36","author":"Will","year":"2000","journal-title":"Eur J Can"},{"key":"10.1016\/j.jval.2013.03.1625_bib29","unstructured":"Ontario Case Costing Initiative. 2011. Available from: http:\/\/www.occp.com\/. [Accessed December 2, 2011]."},{"key":"10.1016\/j.jval.2013.03.1625_bib30","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s11136-007-9202-8","article-title":"Health related quality of life in different states of breast cancer","volume":"16","author":"Lidgren","year":"2007","journal-title":"Qual Life Res"},{"key":"10.1016\/j.jval.2013.03.1625_bib31","series-title":"Decision Modelling for Health Economic Evaluation","author":"Briggs","year":"2006"},{"issue":"3","key":"10.1016\/j.jval.2013.03.1625_bib32","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/annonc\/mdr278","article-title":"Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer","volume":"23","author":"Albanell","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jval.2013.03.1625_bib33","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.amjsurg.2008.06.021","article-title":"Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer?","volume":"196","author":"Asad","year":"2008","journal-title":"Am J Surg"},{"key":"10.1016\/j.jval.2013.03.1625_bib34","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/jso.21244","article-title":"The influence of a gene expression profile on breast cancer decisions","volume":"99","author":"Henry","year":"2009","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.jval.2013.03.1625_bib35","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1200\/JOP.0742001","article-title":"Impact of a commercial reference laboratory test recurrence score on decision making in early-stage breast cancer","volume":"3","author":"Oratz","year":"2007","journal-title":"J Oncol Pract Am Soc Clin Oncol"},{"key":"10.1016\/j.jval.2013.03.1625_bib36","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3747\/co.v17i2.498","article-title":"Febrile neutropenia rates with adjuvant docetaxel and cyclophosphamide chemotherapy in early breast cancer: discrepancy between published reports and community practice\u2014a retrospective analysis","volume":"17","author":"Vandenberg","year":"2010","journal-title":"Curr Oncol"},{"issue":"10","key":"10.1016\/j.jval.2013.03.1625_bib37","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1007\/s00520-011-1375-6","article-title":"Primary G-CSF prophylaxis for adjuvant TC or FEC-D chemotherapy outside of clinical trial settings: a systematic review and meta-analysis","volume":"20","author":"Younis","year":"2012","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jval.2013.03.1625_bib38","unstructured":"Statistics Canada. Consumer price index, health and personal care: Ontario. 2011. Available from: http:\/\/www.statcan.gc.ca. [Accessed December 2, 2011]."},{"key":"10.1016\/j.jval.2013.03.1625_bib39","first-page":"313","article-title":"Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer","volume":"11","author":"Hornberger","year":"2005","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.jval.2013.03.1625_bib40","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1002\/cncr.22506","article-title":"Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies","volume":"109","author":"Lyman","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.jval.2013.03.1625_bib41","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s10549-007-9842-y","article-title":"Economic evaluation of 21-gene reverse transcriptase-polymerase chain reaction assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer in Japan","volume":"112","author":"Kondo","year":"2008","journal-title":"Breast Can Res Treat"},{"key":"10.1016\/j.jval.2013.03.1625_bib42","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s10549-010-1243-y","article-title":"Economic evaluation of the 21-gene signature (Oncotype DX) in lymph node-negative\/positive, hormone receptor-positive early-stage breast cancer based on Japanese validation study (JBCRG-TR03)","volume":"127","author":"Kondo","year":"2011","journal-title":"Breast Can Res Treat"},{"key":"10.1016\/j.jval.2013.03.1625_bib43","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1524-4733.2010.00724.x","article-title":"Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organization","volume":"13","author":"Klang","year":"2010","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2013.03.1625_bib44","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/gim.2012.119","article-title":"Cost-effectiveness of the 21-gene recurrence score assay in the context of multifactorial decision making to guide chemotherapy for early-stage breast cancer","volume":"15","author":"Reed","year":"2013","journal-title":"Genet Med"},{"key":"10.1016\/j.jval.2013.03.1625_bib45","unstructured":"Breastcancer.org. Oncotype DX test. Available from: http:\/\/www.breastcancer.org\/symptoms\/testing\/types\/oncotype_dx.jsp#insurance. [Accessed February 27, 2013]."},{"key":"10.1016\/j.jval.2013.03.1625_bib46","unstructured":"National Institute for Health and Clinical Excellence. Diagnostics consultation document\u2014Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management: MammaPrint, Oncotype DX, IHC4 and Mammostrat. London, UK: National Institute for Health and Clinical Excellence (NICE), February, 2013."},{"key":"10.1016\/j.jval.2013.03.1625_bib47","unstructured":"OHTAC. OHTAC Recommendation: Multi-Gene Expression Profiling for Guiding Adjuvant Chemotherapy Decisions in Women with Early Breast Cancer. Toronto, ON, Canada: the Ontario Health Technology Advisory Committee (OHTAC), December, 2010."},{"key":"10.1016\/j.jval.2013.03.1625_bib48","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1586\/erm.09.32","article-title":"MammaPrint 70-gene signature: another milestone in personalized medical care for breast cancer patients","volume":"9","author":"Slodkowska","year":"2009","journal-title":"Expert Rev Molec Diag"},{"key":"10.1016\/j.jval.2013.03.1625_bib49","doi-asserted-by":"crossref","first-page":"R47","DOI":"10.1186\/bcr2604","article-title":"Mammostrat\u00ae as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy","volume":"12","author":"Bartlett","year":"2010","journal-title":"BCR"},{"key":"10.1016\/j.jval.2013.03.1625_bib50","doi-asserted-by":"crossref","first-page":"4273","DOI":"10.1200\/JCO.2010.31.2835","article-title":"Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the genomic health recurrence score in early breast cancer","volume":"29","author":"Cuzick","year":"2011","journal-title":"J Clin Oncol"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301513016987?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301513016987?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,16]],"date-time":"2019-07-16T22:19:43Z","timestamp":1563315583000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301513016987"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["S1098301513016987"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2013.03.1625","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7]]}}}